Product Data Sheet

ELOVL1-IN-3

Cat. No.: HY-145272 CAS No.: 2761063-99-2 Molecular Formula: $C_{21}H_{23}N_{5}O_{2}$ Molecular Weight: 377.44 Target: Others Pathway: Others

Storage: Pure form -20°C 3 years

> In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (264.94 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6494 mL	13.2471 mL	26.4943 mL
	5 mM	0.5299 mL	2.6494 mL	5.2989 mL
	10 mM	0.2649 mL	1.3247 mL	2.6494 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1)
	enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD) $^{[1]}$.

 $\mathsf{ELOVL1}^{[1]}$ IC₅₀ & Target

REFERENCES

1]. Boyd MJ, et al. Discovery of	Novel, Orally Bioavailable Pyri	midine Ether-Based Inhibitors o	of ELOVL1. J Med Chem. 2021;64(24):17777-17794.	
			dical applications. For research use only.	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.com uth Junction, NJ 08852, USA	
	Address. 1 D	eer rank Dr., Suite Q., Mollillo	util Juliction, NJ 00032, USA	

Page 2 of 2 www.MedChemExpress.com